Preclinical studies have demonstrated that HDAC6 inhibition enhances the efficacy of anti-PD-1/PD-L1 immunotherapy in cancers such as melanoma [61,62], ovarian cancer [63], chronic lymphocytic leukemia [57], and colorectal cancer [56]. The gene discussed is HDAC6; the disease is melanoma.